Burning rock provides an update on 2022 revenue guidance

Guangzhou, china, jan. 17, 2023 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today announced that it expects the company's full-year revenue growth for 2022 to be approximately 10% compared to that of 2021. this represents an upward revision compared with the company's previous guidance on the full-year revenue growth of 5% as announced on november 15, 2022 in its financial results for the third quarter of 2022.
BNR Ratings Summary
BNR Quant Ranking